Press release
Fulcrum Therapeutics® to Participate at the Upcoming Stifel 2022 Biotech Summer Summit
CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving
About this update from Fulcrum Therapeutics, Inc.
[{"type":"text","content":"CAMBRIDGE, Mass., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Stifel 2022 Biotech Summer Summit, on Wednesday, August 17, 2022 at 11:30 a.m. ET. About Fulcrum Therapeutics Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet need. Fulcrum’s two lead programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease (SCD) and other hemoglobinopathies, including beta-thalassemia. The company’s proprietary product engine, FulcrumSeek™, identifies drug targets that can modulate gene expression to treat the known root cause of gene mis-expression. For more information, please visit www.fulcrumtx.com. Contacts: InvestorsStephanie AscherStern Investor Relations, [email protected] MediaDee SmithExecutive Director, Corporate CommunicationsFulcrum Therapeutics, Inc. [email protected] \nSource: Fulcrum Therapeutics, Inc.","length":3550,"tagName":"div"}]